In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser. Current Active Cancer Clinical Trials

Current Active Cancer Clinical Trials 

For additional information about Clinical Trials at the Virginia G. Piper Cancer Center please contact the Clinical Trial Patient Care Coordinator at 480-323-1339 (toll free: 1-877-273-3713), or e-mail clinicaltrials@shc.org. 

 

 

 

Find active Clinical Trials such as Solid Tumors click on a letter below:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

B

BASAL CELL CARCINOMA 

  • A Phase 1 Dose-escalation study of LY2940680 in patients with Advanced Cancer

BLADDER

  • A Phase 1 Study of Oral Azacitidine as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors

BRCA1 OR BRCA2 POSITIVE TUMORS

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors

BREAST CANCER 

  • An open-label, Phase 1, Dose-Escalation Study evaluating the safety and tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Tumors.

TRIPLE NEGATIVE BREAST CANCER

  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

TOP OF PAGE

C

COLON

  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

TOP OF PAGE

E

ENDOMETRIAL

  • An open-label, Phase 1, Dose-Escalation Study evaluating the safety and tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Tumors.

TOP OF PAGE

F

FALLOPIAN TUBE

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors)

TOP OF PAGE

G

GASTRIC

  • A Multicenter Phase 1/1b open label dose escalation study of ABT-700 a monoclonal antibody in subjects with advanced solid tumors.

TOP OF PAGE

H

TOP OF PAGE

L

LIVER

  • A Phase I, multicenter study of MRX34 given intravenously two times per week for three weeks, repeated every four weeks in patients with unresectable primary liver cancer or advanced or metastatic cancer with liver involvement.

LUNG - NSCLC

  • A Multicenter Phase 1/1b open label dose escalation study of ABT-700 a monoclonal antibody in subjects with advanced solid tumors
  • A Phase 1 Study of Oral Azacitidine as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors
  • A Phase 1, Multicenter, Open-label, Dose-escalation study of LY2812176 given intravenously weekly in patients with Multiple Myeloma or Advanced Solid Tumors
  • A Pilot Study in Patients Treated with MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages

LUNG - SCL

  • A Phase 1/2, First in Human, Single arm, open label study of once a day, orally administered BMN 673 in patients with Advanced or Recurrent Tumors - BRCA POSITIVE

LYMPHOMA 

  • An Open Label Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, maximum tolerated dose and bio-marker response after intravenous administration of weekly BAY 80-6946 to patients with advanced cancer.
  • A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

TOP OF PAGE

M

MELANOMA - BRAF POSITIVE 

  • A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of SCH 900353 in Subjects With Advanced Solid Tumors

TOP OF PAGE

N

TOP OF PAGE

O

OVARIAN CANCER

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors
  • A Phase 1 Study of Oral Azacitidine as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors

TOP OF PAGE

P

PANCREATIC CANCER 

  • A Phase 1/2, First in Human, Single arm, open label study of once a day, orally administered BMN 673 in patients with Advanced or Recurrent Tumors - BRCA POSITIVE
  • A Phase 1b Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and nab-Paclitaxel in Subjects With Advanced Solid Tumors
  • A Randomized, Open Label Phase III Study of MM-398 versus 5-Fluorouracil and Leucovorin in Patients with Metastatic Pancreatic Cancer
  • A Phase IB/II Pilot Trial of Nab-Paclitaxel plus Cisplatin Plus Gemcitabine (NABPLAGEM) in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (website pending)
  • SEENA TRIAL - A Phase II Study of Induction and Consolidation and Maintenance approach for patient with Advanced Pancreatic Cancer  - PCRT 11-002
  • SU2C-005 - A Phase I/II pharmacodynamic study of hydroxychloroquine in combination with Gemcitabine/abraxane to inhibit autophagy in Pancreatic cancer.

PERITONEAL

  • A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib - ABT-888 - Extended Release Formulations in Subjects with Solid Tumors

PROSTATE

  • A Phase 1/2, First in Human, Single arm, open label study of once a day, orally administered BMN 673 in patients with Advanced or Recurrent Tumors - BRCA Positive -

TOP OF PAGE

R

RECTAL

  • An Open-Label Phase 1b Study of the Safety and Tolerability of Veliparib in Combination with Capecitabine and Radiation in Subjects with Locally Advanced Rectal Cancer (LARC)

TOP OF PAGE

S

SARCOMA - EWINGS

  • A Phase 1/2, First in Human, Single arm, open label study of once a day, orally administered BMN 673 in patients with Advanced or Recurrent Tumors - BRCA POSITIVE

SOLID TUMORS

  • A Multicenter Phase 1/1b open label dose escalation study of ABT-700 a monoclonal antibody in subjects with advanced solid tumors.
  • A Phase 1 Open-Label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of BAX69 in subject with malignant solid tumors
  • A Phase 1b trial of the combination of PI3(Phosphoinositol 3)-K inhibitor BAY 80-6946 and MEK(Mitogen-activated Protein Kinase) inhibitor BAY 86-9766 in subjects with advanced cancer.
  • A Phase 1 open label, safety and pharmacokinetic and pharmacodynamic dose escalation study of  BIND 014 given by infusion to patients with advanced or metastatic cancer.
  • An open-label, Phase 1, Dose-Escalation Study evaluating the safety and tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Tumors.
  • A Phase 1b Study of the Safety and Tolerability of INCB039110 in Combination With Gemcitabine and nab-Paclitaxel in Subjects With Advanced Solid Tumors
  • A Phase 1, Multicenter, Open-label, Dose-escalation study of LY2812176 given intravenously weekly in patients with Multiple Myeloma or Advanced Solid Tumors
  • A Phase 1 Dose-escalation study of LY2940680 in patients with Advanced Cancer
  • A Phase I, multicenter study of MRX34 given intravenously two times per week for three weeks, repeated every four weeks in patients with unresectable primary liver cancer or advanced or metastatic cancer with liver involvement.
  • A Phase I/II, Multi-center, open label, dose escalation trial of the safety and Pharmacokinetics of Intravenous PR610 given weekly in subjects with solid tumors
  • A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects with Selected HER2 Positive Cancers
  • A Phase 1, Open-Label, Randomized, Crossover study evaluating the bioavailability of TAS-102 tablets relative to an oral solution containing equivalent amounts of FTD and TPI in Advanced Solid Tumors (excluding breast cancer) for which no standard therapy exists
  • A Phase 1 Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM-080301 in Patients with Advanced Solid Tumors.
  • A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas
  • A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamins of Intravenous Infusion of VX15/2503 in Adult Patients with Advanced Solid Tumors

TOP OF PAGE

Contact Us:

printer